ByteBrief
We're a portrait publication through and through. Turn your phone back and your briefing picks up right where you left it.
(We tried widescreen once. It wasn't us.)
AI drug discovery is advancing, with companies moving candidates into clinical trials. The technology accelerates target identification and molecule design, though regulatory and validation hurdles remain. Real-world results are emerging, showing both promise and limitations in the field.
Tap to vote and see what everyone thinks.
Summary by ByteBrief